Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Adavosertib (Primary) ; Darolutamide (Primary) ; Savolitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- Acronyms PC-BETS
- 27 May 2019 Planned End Date changed from 31 Dec 2020 to 31 Dec 2021.
- 31 Aug 2018 Biomarkers information updated
- 21 Mar 2018 Status changed from not yet recruiting to recruiting.